Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Blood (2019) 133 (13): 1457–1464.

https://doi.org/10.1182/blood-2018-10-879866

Published: 2019

Includes: Supplemental data

Journal Articles

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert Huls, MD PhD, Dana Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, MD PhD, Arjen van de Loosdrecht, Bart J. Biemond, MD PhD, Harm Sinnege, MDPhD, Beata Hodossy, Carlos Graux, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Dimitri Breems, MD PhD, Saskia Klein, MD, Jurgen Kuball, MD, Gert J. Ossenkoppele, MD PhD, Bob Lowenberg, MD PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 463.

https://doi.org/10.1182/blood.V130.Suppl_1.463.463

Published: 2017

Journal Articles

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Blood (2017) 130 (Supplement 1): 2606.

https://doi.org/10.1182/blood.V130.Suppl_1.2606.2606

Published: 2017

Journal Articles

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Blood (2012) 120 (24): 4706–4711.

https://doi.org/10.1182/blood-2012-04-420596

Published: 2012

Includes: Supplemental data

Journal Articles

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Gert Ossenkoppele, MD, PhD, Bob Lowenberg, MD, PhD, Pierre Zachee, MD, PhD, Norbert Vey, Dimitri Breems, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD, Phillip Debnam, PhD, Lindsey Needham, PhD, Lindsay Bawden, PhD, Leon Hooftman, MD

Blood (2010) 116 (21): 3279.

https://doi.org/10.1182/blood.V116.21.3279.3279

Published: 2010

Journal Articles

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Blood (2010) 115 (13): 2586–2591.

https://doi.org/10.1182/blood-2009-10-246470

Published: 2010

Journal Articles

Treatment of Older Patients, 40 to 70 Years of Age, with Acute Lymphoblastic Leukemia According to a Chemotherapy Regimen That Includes a Novel Pre-Phase for Rapid Tumor Load Reduction. Results of the Dutch-Belgian HOVON-71 Study.

Simon M. G. J. Daenen, Bronno van der Holt, Adriaan W. Dekker, Roelof Willemze, Anita Rijneveld, Bart J. Biemond, Petra Muus, Arjan A van de Loosdrecht, Harry Schouten, M. van Marwijk Kooy, Dimitri Breems, Johan Maertens, Hilde Demuynck, Pierre W Wijermans, Shulamiet Wittebol, Ellen W. de Klerk, Jan J. Cornelissen

Blood (2009) 114 (22): 2028.

https://doi.org/10.1182/blood.V114.22.2028.2028

Published: 2009

Journal Articles

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

Faith Davies, MD, Gert Ossenkoppele, MD, Pierre Zachee, MD, Richard Noppeney, MD, Alan Burnett, MD, Michel Delforge, MD, Pieter Sonneveld, MD, Gareth Morgan, MD, Sonja Zweegman, MD, Dimitri Breems, MD, Alison Richardson, PhD, Leon Hooftman, MD, Bob Lowenberg, MD

Blood (2007) 110 (11): 443.

https://doi.org/10.1182/blood.V110.11.443.443

Published: 2007

NARROW

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Treatment of Older Patients, 40 to 70 Years of Age, with Acute Lymphoblastic Leukemia According to a Chemotherapy Regimen That Includes a Novel Pre-Phase for Rapid Tumor Load Reduction. Results of the Dutch-Belgian HOVON-71 Study.

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only